FDA gives green light for Regeneron's 12-week Eylea regimen

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA approved an sBLA for an every 12-week dosing schedule of Eylea aflibercept to treat wet age-related

Read the full 222 word article

User Sign In